Skip NavigationSkip to Content
Return Return to Search Results

Race-specific prostate cancer outcomes in a cohort of low and favorable-intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017

  1. Author:
    Stroup, Sean P
    Robertson, Audry H
    Onofaro, Kayla C [ORCID]
    Santomauro, Michael G
    Rocco, Nicholas R
    Kuo, Huai-Ching
    Chaurasia, Avinash R
    Streicher, Samantha [ORCID]
    Nousome,Darryl
    Brand, Timothy C
    Musser, John E
    Porter, Christopher R
    Rosner, Inger L
    Chesnut, Gregory T
    D'Amico, Anthony
    Lu-Yao, Grace [ORCID]
    Cullen, Jennifer [ORCID]

  2. Author Address

    Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Department of Urology, Naval Medical Center San Diego, San Diego, California, USA., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA., Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Department of Radiation Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA., Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Madigan Army Medical Center, Tacoma, Washington, USA., Tripler Army Medical Center, Honolulu, Hawaii, USA., Virginia Mason Medical Center, Seattle, Washington, USA., Urology Service, Department of Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA., INOVA, Falls Church, Virginia, USA., Department of Radiation Oncology, Brigham and Women 39;s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Department of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson, Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA., Sidney Kimmel Cancer Center at Jefferson, Philadelphia, Pennsylvania, USA., Philadelphia, Jefferson College of Population Health, Pennsylvania, USA., Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA., Case Comprehensive Cancer Center, Cleveland, Ohio, USA.,
    1. Year: 2022
    2. Date: May 26
    3. Epub Date: 2022 05 26
  2. Journal: Cancer Medicine
  4. Type of Article: Article
  1. Abstract:

    Previous research exploring the role of race on prostate cancer (PCa) outcomes has demonstrated greater rates of disease progression and poorer overall survival for African American (AA) compared to Caucasian American (CA) men. The current study examines self-reported race as a predictor of long-term PCa outcomes in patients with low and favorable-intermediate risk disease treated with external beam radiation therapy (EBRT). This retrospective cohort study examined patients who were consented to enrollment in the Center for Prostate Disease Research Multicenter National Database between January 01, 1990 and December 31, 2017. Men self-reporting as AA or CA who underwent EBRT for newly diagnosed National Comprehensive Cancer Network-defined low or favorable-intermediate risk PCa were included. Dependent study outcomes included: biochemical recurrence-free survival, (ii) distant metastasis-free survival, and (iii) overall survival. Each outcome was modeled as a time-to-event endpoint using race-stratified Kaplan-Meier estimation curves and multivariable Cox proportional hazards analysis. Of 840 men included in this study, 268 (32%) were AA and 572 (68%) were CA. The frequency of biochemical recurrence, distant metastasis, and deaths from any cause was 151 (18.7%), 29 (3.5%), and 333 (39.6%), respectively. AA men had a significantly younger median age at time of EBRT and slightly higher biopsy Gleason scores. Multivariable Cox proportional hazards analyses demonstrated no racial differences in any of the study endpoints. These findings reveal no racial disparity in PCa outcomes for AA compared to CA men, in a long-standing, longitudinal cohort of patients with comparable access to cancer care. © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/cam4.4802
  3. PMID: 35616266

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel